Observational studyJournal of cachexia, sarcopenia and muscle2026
A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA).
Observational study in Journal of cachexia, sarcopenia and muscle, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction to 'A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA)'.Journal of cachexia, sarcopenia and muscle · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
22 authors.
Funding
Abstract
backgroundThe prognosis of patients with advanced non-small cell lung cancer (NSCLC) complicated by cancer cachexia remains poor. Anamorelin, a ghrelin receptor agonist, has been approved only in Japan for the treatment of cancer cachexia.
methodsThis prospective multicentre observational study was conducted to evaluate the impact of anamorelin administration on the efficacy and safety of chemoimmunotherapy in patients with NSCLC and cancer cachexia. The primary endpoint was progression-free survival (PFS), evaluated against a predefined threshold derived from a previous retrospective cohort of patients with cachectic NSCLC treated with chemoimmunotherapy alone. This study was registered in the Japan Registry of Clinical Trials (jRCT1071210053).
resultsBetween August 2021 and January 2024, 123 patients were enrolled from 29 institutions in Japan, with 114 included in the full analysis set. The median age was 73 years; 28 (24.6%) were female and 20 patients (17.5%) had a performance status of 2. The objective response rate was 57.9% (95% confidence interval [CI]: 48.7%-66.6%). Median PFS and overall survival (OS) were 6.2 months (95% CI: 4.6-7.7) and 18.5 months (95% CI: 13.1-28.6), respectively. The lower limit of the 95% CI for PFS did not exceed the predefined threshold of 5 months. At week 12, 61 of 85 patients (71.8%) had transitioned from cancer cachexia to a non-cachectic state. Landmark survival analyses at week 12 showed that patients who achieved this transition had significantly longer OS compared with those who remained cachectic (19.9 vs. 7.1 months; hazard ratio for cachexia vs. transition, 2.19; 95% CI: 1.19-4.02; p = 0.0098). Grade ≥ 3 hyperglycemia was observed in six patients (5.1%), but no new safety signals were identified.
conclusionsAnamorelin combined with chemoimmunotherapy did not prolong PFS in advanced NSCLC with cancer cachexia, but achieved a high rate of cachexia reversal. Transition to a non-cachectic state was associated with improved OS, suggesting that cachexia reversal may serve as a surrogate for survival benefit.
trial registrationjRCT1071210053 (jRCT).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.